Latest database descriptions

Primary objective : To assess the drug retention rate of TCZ sc at 12 months under real-world conditions in patients with moderate to severe active RA followed by hospital- and office-based rheumatologists
Secondary objectives :
- To assess the drug retention rate of TCZ sc at 6 and 18 months.
- To compare the drug retention of TCZ sc in monotherapy and in combination with MTX or other csDMARD.
- To describe steroid dosing after introduction of TCZ sc with a stratification on the use of MTX or other csDMARDs at 6, 12 and 18 months.
- To assess adherence to TCZ sc using a French version of the Compliance Questionnaire for Rheumatology 5 (CQR5) and patient diary at 6, 12 and 18 months.
- To evaluate the French version of the CQR5 by assessing the correlation with the data collected from the patient diary data.
- To describe the modalities of use of TCZ sc.
- To describe the management of RA and patients’ healthcare pathway between hospital- and office-based rheumatologists.
- To describe the efficacy of TCZ sc under real-world conditions of use.
- To describe the characteristics of patients treated with TCZ sc and the characteristics of the involved physicians.
- To assess the tolerability profile of TCZ sc under real-world conditions of use.
- To describe the quality of life (QoL) in patients receiving TCZ sc under real-world conditions of use.

In each cohort of patients defined by their age classification ([65; 70[ and >=70 years), outcome measures are as follows:
- Antineoplastic agents combined with bevacizumab as 1st line therapy
- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,…)
- Supportive care (growth factors, analgesics).
to describe:
- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,
- Progression-Free Survival (PFS) and Overall Survival (OS),
- Evolution of patients’ quality of life over the treatment period with bevacizumab as first-line therapy,
- Safety of bevacizumab,
- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

Primary objective : To describe in real-life conditions the insulin resistance and its impact on SVR in patients presenting with chronic hepatitis C and treated with Pegasys® and Copegus®.
Secondary objectives :
- To describe patients’ characteristics at inclusion
- To describe the predictive factors influencing virological response under treatment at W4 (rapid virological response, RVR), at W12 (early virological response, EVR), and 24 weeks after the end of treatment with Pegasys® (sustained virological response, SVR)
- To describe the constitutive parameters of metabolic syndrome during the study period
- To describe the management of chronic hepatitis C and insulin resistance
- To describe the changes in patients’ quality of life during the study period
- To describe the serious and non-serious adverse events occurring during the study period.

This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice
1. To describe characteristics of patients treated with Avastin®: demographic and clinical characteristics, history of the disease, and previous disorders and conditions,
2. To describe methods of use of Avastin® in follow-up: doses and durations of treatment with Avastin® (number of cycles); chemotherapy treatments used in combination with treatment with Avastin®; discontinuation of treatment with Avastin® (temporary and permanent) and reasons; treatment strategies set up after discontinuation of treatment with Avastin®,
3. To describe overall survival of patients treated with Avastin®,
4. To describe the safety profile of treatment with Avastin®: serious and non-serious adverse events and targeted adverse events,
5. To describe quality of life: Spitzer's quality of life questionnaire,
6. To describe therapeutic management of patients with non-squamous cell NSCLC in first-line chemotherapy of metastatic disease not receiving Avastin®: compilation of an anonymous registry over a 3-month period starting with time of scientific set up by the investigator.